Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
Go back to Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis| Johnson & Johnson (NYSE: JNJ) | Delayed: 269.41 -0.81 (0.3%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $270.22 | 52 Week High | $126.07 | |||
| Open | $268.75 | 52 Week Low | $94.28 | |||
| Day High | $269.76 | P/E | 56.01 | |||
| Day Low | $267.86 | EPS | $4.81 | |||
| Volume | 1,623,798 | |||||
